中生北控生物科技(08247.HK)委任陳鵬等5人為公司董事
格隆匯5月25日丨中生北控生物科技(08247.HK)宣佈,由於林楊林、程亞利及鄭永唐的董事任期已於股東周年大會上屆滿且彼等均因希望投入更多時間在其他事務而不願意接受重新委任,(a林楊林不再擔任執行董事;(b)程亞利不再擔任非執行董事;及(c)鄭永唐不再擔任獨立非執行董事、審核委員會及薪酬委員會各自之主席以及提名委員會成員,均自2023年5月25日起生效。
董事會進一步宣佈,相關委任獲股東於股東周年大會上批准後,陳鵬已獲委任為執行董事,陳正永、李忠華及高光俠已各自獲委任為非執行董事,沈佐君已獲委任為獨立非執行董事,均自2023年5月25日起生效。
董事會進一步宣佈,沈佐君獲委任為獨立非執行董事後,彼亦獲委任為薪酬委員會之主席以及審核委員會及提名委員會各自之成員,自2023年5月25日起生效。陸琪已獲委任為審核委員會主席,自2023年5月58日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.